XML 63 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Significant agreements - Sanofi Collaboration Agreement (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Aug. 31, 2017
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Significant agreements.              
Revenue recognized by non exercising of option   $ 0 $ 0   $ 5,286    
Revenue from collaborative arrangement   1,571 1,522 $ 2,700 7,906    
Deferred revenue   33,082   33,082   $ 5,657 $ 14,635
Development milestone              
Significant agreements.              
Non refundable payment for services during the BV Bicycle Research Term       4,200      
Sanofi              
Significant agreements.              
Total transaction price initially determined $ 14,200         14,900  
Upfront cash payment 10,000            
Non refundable payment for services during the BV Bicycle Research Term 4,200            
Revenue from collaborative arrangement   0 57 0 $ 6,016    
Deferred revenue   $ 0   $ 0   $ 0 $ 9,908
Sanofi | Sickle Cell Research License and Related Services              
Significant agreements.              
Total transaction price initially determined 1,405            
Sanofi | Hemophilia Research License and Related Services              
Significant agreements.              
Total transaction price initially determined 2,811            
Sanofi | Sickle Cell License Option Material Right              
Significant agreements.              
Total transaction price initially determined 5,286            
Revenue recognized by non exercising of option     $ 5,300        
Sanofi | Hemophilia License Option Material Right              
Significant agreements.              
Total transaction price initially determined $ 4,698